Justin Lawson1, Jeffrey M Switchenko2, Trevor McKibbin1,3, R Donald Harvey3,4. 1. Department of Pharmaceutical Services, Emory Healthcare, Atlanta, Georgia. 2. Biostatistics & Bioinformatics Shared Resource, Rollins School of Public Health, Winship Cancer Institute of Emory University, Atlanta, Georgia. 3. Department of Hematology and Medical Oncology, School of Medicine, and Winship Cancer Institute, Emory University, Atlanta, Georgia. 4. Department of Pharmacology, School of Medicine, Emory University, Atlanta, Georgia.
Abstract
BACKGROUND: When using area under the concentration-time curve-based strategies for dosing carboplatin, accurate estimation of glomerular filtration rate is required for determining dose. Commonly, the Cockcroft-Gault equation is used, which is dependent on measurement of serum creatinine (SCr). Because analysis of SCr changed to an isotope dilution mass spectrometry (IDMS) standard, we sought to determine the impact of this assay change on carboplatin dosing and related toxicity. METHODS: This was a single-center, retrospective chart review of adults treated with carboplatin between April 2008 and April 2010 divided into cohorts that initiated carboplatin before or after IDMS standardization. End points included grade 3 thrombocytopenia, decrease in platelet count, and hospitalization and were evaluated in cohorts based on concomitant chemotherapy. RESULTS: The chart review identified 158 patients, with 63 patients in the pre-IDMS group and 95 patients in the post-IDMS group. Average SCr (pre 1.01 mg/dl vs post 0.86 mg/dl, p<0.001) and average carboplatin dose (pre 580 mg vs post 703 mg, p<0.001) were significantly different between the groups. The frequency of grade 3 thrombocytopenia was not statistically significant across three partner chemotherapy cohorts before and after IDMS implementation. CONCLUSION: IDMS standardization led to an overall decrease in SCr with subsequent increase in carboplatin doses. However, no increase in recorded adverse events was observed, suggesting that the clinical relevance in toxicity from higher doses was minimal.
BACKGROUND: When using area under the concentration-time curve-based strategies for dosing carboplatin, accurate estimation of glomerular filtration rate is required for determining dose. Commonly, the Cockcroft-Gault equation is used, which is dependent on measurement of serum creatinine (SCr). Because analysis of SCr changed to an isotope dilution mass spectrometry (IDMS) standard, we sought to determine the impact of this assay change on carboplatin dosing and related toxicity. METHODS: This was a single-center, retrospective chart review of adults treated with carboplatin between April 2008 and April 2010 divided into cohorts that initiated carboplatin before or after IDMS standardization. End points included grade 3 thrombocytopenia, decrease in platelet count, and hospitalization and were evaluated in cohorts based on concomitant chemotherapy. RESULTS: The chart review identified 158 patients, with 63 patients in the pre-IDMS group and 95 patients in the post-IDMS group. Average SCr (pre 1.01 mg/dl vs post 0.86 mg/dl, p<0.001) and average carboplatin dose (pre 580 mg vs post 703 mg, p<0.001) were significantly different between the groups. The frequency of grade 3 thrombocytopenia was not statistically significant across three partner chemotherapy cohorts before and after IDMS implementation. CONCLUSION: IDMS standardization led to an overall decrease in SCr with subsequent increase in carboplatin doses. However, no increase in recorded adverse events was observed, suggesting that the clinical relevance in toxicity from higher doses was minimal.
Authors: Mário L de Lemos; Teresa Hsieh; Linda Hamata; Adeera Levin; Ken Swenerton; Ognjenka Djurdjev; Thanh Vu; Francis Hu; James Conklin; Suzanne C Malfair Taylor Journal: Gynecol Oncol Date: 2006-07-27 Impact factor: 5.482
Authors: Gary L Myers; W Greg Miller; Josef Coresh; James Fleming; Neil Greenberg; Tom Greene; Thomas Hostetter; Andrew S Levey; Mauro Panteghini; Michael Welch; John H Eckfeldt Journal: Clin Chem Date: 2005-12-06 Impact factor: 8.327
Authors: C P Belani; C M Kearns; E G Zuhowski; K Erkmen; D Hiponia; D Zacharski; C Engstrom; R K Ramanathan; M J Capozzoli; J Aisner; M J Egorin Journal: J Clin Oncol Date: 1999-02 Impact factor: 44.544
Authors: A H Calvert; S J Harland; D R Newell; Z H Siddik; A C Jones; T J McElwain; S Raju; E Wiltshaw; I E Smith; J M Baker; M J Peckham; K R Harrap Journal: Cancer Chemother Pharmacol Date: 1982 Impact factor: 3.333
Authors: Anand Joshi; Jianxia Guo; Julianne L Holleran; Brian Kiesel; Sarah Taylor; Susan Christner; Robert A Parise; Brian M Miller; S Percy Ivy; Edward Chu; Raman Venkataramanan; Jan H Beumer Journal: Cancer Chemother Pharmacol Date: 2020-09-18 Impact factor: 3.333